Akito Miyazaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akito Miyazaki has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Akihiro Tamiya
Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, 1180, Nagasone-cho Kita-ku, Sakai, Osaka, 591-8555, Japan
3 shared publicationsAkio Osa
Department of Respiratory Medicine, Kinki Central Hospital, 3-1 Kurumazuka, Itami City, Hyogo, 664-8533, Japan
3 shared publicationsHidekazu Suzuki
Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino-shi, Osaka, 583-8588, Japan
3 shared publications- Hirotomo Machiyama
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, the University of Osaka, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan; Department of Immunogenomic Medicine, Research Institute, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
3 shared publications - Kei Kunimasa
Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
3 shared publications Keijiro Yamauchi
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, the University of Osaka, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan; Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino-shi, Osaka, 583-8588, Japan
3 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Elsevier in ESMO Rare Cancers
- Vol. 7
First-line MET inhibitors versus immune checkpoint inhibitor–based regimens in MET exon 14 skipping mutation positive NSCLC: a multicenter real-world cohort study in Japan
- 7 September 2026
- Published by Elsevier in ESMO Rare Cancers
- Vol. 7
Open AccessFirst-line MET inhibitors versus immune checkpoint inhibitor–based regimens in MET exon 14 skipping mutation positive NSCLC: a multicenter real-world cohort study in Japan
- Open Access
- 6 January 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (4) , 100953
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study
- 6 January 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (4) , 100953
Open AccessClinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study
- Open Access
- 8 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 210, 108835
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study
- 8 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 210, 108835
Open AccessLong-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study
- Open Access
- 14 April 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 8, 100137
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study
- 14 April 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 8, 100137
Open AccessComparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study
- Open Access
- 3 February 2024
- Published by Elsevier in Lung Cancer
- Vol. 189, 107498
Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer
- 3 February 2024
- Published by Elsevier in Lung Cancer
- Vol. 189, 107498
Open AccessClinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer